{"preliminary_commentary":{"by_channel":{"x_thread":12,"podcast":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05676203\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["docetaxel"]],"indication":"metastatic hormone-sensitive prostate cancer","name":"ARASAFE","nct_id":"NCT05676203","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=arasafe-nct05676203. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"ARASAFE","arms":[{"description":"6 x Docetaxel 75 mg/m2 every 3 weeks of a 3 week cycle Co-administration of docetaxel, darolutamide and standard ADT","label":"Arm 1","type":"ACTIVE_COMPARATOR"},{"description":"6 x Docetaxel 50 mg/ m2 every 2 weeks of a 4 week cycle Co-administration of docetaxel, darolutamide and standard ADT","label":"Arm 2","type":"EXPERIMENTAL"}],"collaborators":["Bayer"],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)"],"enrollment":{"count":250,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Standard ADT (androgen deprivation therapy)","otherNames":[],"type":"DRUG"},{"name":"Standard Darolutamide","otherNames":[],"type":"DRUG"},{"name":"Docetaxel","otherNames":[],"type":"DRUG"}],"last_update":"2026-08-05","lead_sponsor":"Jena University Hospital","official_title":"A Randomised, Phase 3 Trial Comparing 3-weekly Docetaxel 75 mg/m2 (in a 3 Week Cycle) Versus 2-weekly Docetaxel 50 mg/m2 (in a 4 Week Cycle) in Combination With Darolutamide + ADT in Patients With mHSPC","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-07-03","type":"ACTUAL"},"primary_outcomes":[{"measure":"Rate of grade 3-5 AEs","timeFrame":"28 weeks after last patient first Docetaxel dose (LPFD)"}],"references":[],"start_date":{"date":"2023-05-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients","url":"https://clinicaltrials.gov/study/NCT05676203"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/arasafe-nct05676203"}